Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin.
Emergency department
Hospital admission
MR-proADM
Mortality
SARS-CoV-2
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
28 Aug 2022
28 Aug 2022
Historique:
received:
22
12
2021
accepted:
08
08
2022
entrez:
28
8
2022
pubmed:
29
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
Mid-Regional pro-Adrenomedullin (MR-proADM) is an inflammatory biomarker that improves the prognostic assessment of patients with sepsis, septic shock and organ failure. Previous studies of MR-proADM have primarily focussed on bacterial infections. A limited number of small and monocentric studies have examined MR-proADM as a prognostic factor in patients infected with SARS-CoV-2, however there is need for multicenter validation. An evaluation of its utility in predicting need for hospitalisation in viral infections was also performed. An observational retrospective analysis of 1861 patients, with SARS-CoV-2 confirmed by RT-qPCR, from 10 hospitals across Europe was performed. Biomarkers, taken upon presentation to Emergency Departments (ED), clinical scores, patient demographics and outcomes were collected. Multiclass random forest classifier models were generated as well as calculation of area under the curve analysis. The primary endpoint was hospital admission with and without death. Patients suitable for safe discharge from Emergency Departments could be identified through an MR-proADM value of ≤ 1.02 nmol/L in combination with a CRP (C-Reactive Protein) of ≤ 20.2 mg/L and age ≤ 64, or in combination with a SOFA (Sequential Organ Failure Assessment) score < 2 if MR-proADM was ≤ 0.83 nmol/L regardless of age. Those at an increased risk of mortality could be identified upon presentation to secondary care with an MR-proADM value of > 0.85 nmol/L, in combination with a SOFA score ≥ 2 and LDH > 720 U/L, or in combination with a CRP > 29.26 mg/L and age ≤ 64, when MR-proADM was > 1.02 nmol/L. This international study suggests that for patients presenting to the ED with confirmed SARS-CoV-2 infection, MR-proADM in combination with age and CRP or with the patient's SOFA score could identify patients at low risk where outpatient treatment may be safe.
Sections du résumé
BACKGROUND
BACKGROUND
Mid-Regional pro-Adrenomedullin (MR-proADM) is an inflammatory biomarker that improves the prognostic assessment of patients with sepsis, septic shock and organ failure. Previous studies of MR-proADM have primarily focussed on bacterial infections. A limited number of small and monocentric studies have examined MR-proADM as a prognostic factor in patients infected with SARS-CoV-2, however there is need for multicenter validation. An evaluation of its utility in predicting need for hospitalisation in viral infections was also performed.
METHODS
METHODS
An observational retrospective analysis of 1861 patients, with SARS-CoV-2 confirmed by RT-qPCR, from 10 hospitals across Europe was performed. Biomarkers, taken upon presentation to Emergency Departments (ED), clinical scores, patient demographics and outcomes were collected. Multiclass random forest classifier models were generated as well as calculation of area under the curve analysis. The primary endpoint was hospital admission with and without death.
RESULTS
RESULTS
Patients suitable for safe discharge from Emergency Departments could be identified through an MR-proADM value of ≤ 1.02 nmol/L in combination with a CRP (C-Reactive Protein) of ≤ 20.2 mg/L and age ≤ 64, or in combination with a SOFA (Sequential Organ Failure Assessment) score < 2 if MR-proADM was ≤ 0.83 nmol/L regardless of age. Those at an increased risk of mortality could be identified upon presentation to secondary care with an MR-proADM value of > 0.85 nmol/L, in combination with a SOFA score ≥ 2 and LDH > 720 U/L, or in combination with a CRP > 29.26 mg/L and age ≤ 64, when MR-proADM was > 1.02 nmol/L.
CONCLUSIONS
CONCLUSIONS
This international study suggests that for patients presenting to the ED with confirmed SARS-CoV-2 infection, MR-proADM in combination with age and CRP or with the patient's SOFA score could identify patients at low risk where outpatient treatment may be safe.
Identifiants
pubmed: 36031619
doi: 10.1186/s12931-022-02151-1
pii: 10.1186/s12931-022-02151-1
pmc: PMC9420187
doi:
Substances chimiques
Biomarkers
0
Protein Precursors
0
Adrenomedullin
148498-78-6
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
221Informations de copyright
© 2022. The Author(s).
Références
J Infect. 2018 Jul;77(1):18-24
pubmed: 29807091
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
Clin Chem Lab Med. 2021 Jan 08;59(5):995-1004
pubmed: 33554516
Crit Care. 2019 Oct 29;23(1):335
pubmed: 31665092
Eur J Clin Invest. 2021 May;51(5):e13511
pubmed: 33569769
Stat Med. 2019 Mar 30;38(7):1276-1296
pubmed: 30357870
Front Med (Lausanne). 2021 Jul 09;8:699880
pubmed: 34307426
J Burn Care Res. 2017 Sep/Oct;38(5):290-298
pubmed: 28221298
Crit Care. 2018 Mar 21;22(1):79
pubmed: 29562917
Sci Rep. 2021 Mar 4;11(1):5121
pubmed: 33664308
Intern Emerg Med. 2021 Sep;16(6):1723-1725
pubmed: 33963517
Crit Care. 2020 Jul 9;24(1):411
pubmed: 32646523
J Clin Pathol. 2022 Jan 7;:
pubmed: 34996755
J Transl Med. 2021 Feb 5;19(1):56
pubmed: 33546711
Eur J Intern Med. 2021 Jun;88:104-113
pubmed: 33906810
Int J Infect Dis. 2021 Oct;111:211-218
pubmed: 34461254
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Front Physiol. 2020 Jun 26;11:747
pubmed: 32676039
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Crit Care. 2019 Feb 8;23(1):40
pubmed: 30736862
Expert Rev Mol Diagn. 2021 Apr;21(4):397-404
pubmed: 33736553
BMC Infect Dis. 2011 May 03;11:112
pubmed: 21539743
Med Drug Discov. 2020 Dec;8:100057
pubmed: 32838292
BMJ Open Respir Res. 2020 Dec;7(1):
pubmed: 33293361
PLoS One. 2021 Feb 8;16(2):e0246771
pubmed: 33556140
Clin Infect Dis. 2020 Nov 19;71(16):2199-2206
pubmed: 32407459
Shock. 2016 Mar;45(3):259-70
pubmed: 26871664
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32616597
Clin Chem. 2015 Dec;61(12):1446-52
pubmed: 26510957
J Leukoc Biol. 2018 Apr;103(4):749-759
pubmed: 29360169
Crit Care. 2018 Jun 5;22(1):147
pubmed: 29871660
Intensive Care Med. 2008 Mar;34(3):518-22
pubmed: 18080111